Fabry Disease Treatment Market size is projected to experience significant growth from 2022 to 2028 with rising incidences of this rare disorder around the world. It is an X-linked lysosomal storage disease with a deficiency of an enzyme called alpha-galactosidase which leads to progressive dysfunction of organs.
The rising pervasiveness of this disease has urged the research institutions and pharmaceutical firms to focus on the development of a treatment for Fabry disease. The ongoing research activities coupled with the adoption of advanced technologies in these initiatives are majorly stimulating the industry growth.
The market statistics are estimated to be further strengthened by the presence of potential treatment solutions for Fabry disease that are expected to gain regulatory approval in the coming years. In recent years, several key regulatory bodies have approved novel medications for the disease. The development and clearance for such medications will expedite the growth of market during the forecast period.
Based on the treatment type, the market is bifurcated into Enzyme replacement therapy, Chaperone treatment, substrate reduction therapy, and others. Enzyme replacement therapy segment, however, is anticipated to grow notably over the forthcoming years as this therapy is known to be the only specific treatment for Fabry disease. The effect of this therapy on various organs has been evaluated extensively and is known to have improved the quality of life of patients. The growing awareness regarding Fabry disease within the healthcare community and rising need for timely diagnosis are poised to support the growth of enzyme replacement therapy segment.
Fabry disease treatment market will observe substantial growth in the Asia Pacific during the forecast timeframe on account of the ongoing developments in the regional healthcare infrastructure. Besides, increasing healthcare expenditure in the developing economies which are creating lucrative opportunities for the pharmaceutical companies, is favoring the industry expansion further. In addition, the increasing government initiatives for rare disease treatment will strengthen the industry landscape in the coming years.
The key companies operating in market include JCR Pharmaceuticals Co Ltd., Amicus Therapeutics Inc., Sanofi S.A., Idorsia Pharmaceuticals Ltd., GlaxoSmithKline plc (Unilever), ISU Abxis Co Ltd., Shire Plc., Takeda Pharmaceutical Co. Ltd., Protalix Biotherapeutics Inc. These companies are undergoing strategic collaborations and partnerships to gain a strong foothold in the market.
The COVID-19 pandemic is predicted to increase the demand for the therapeutic solutions for Fabry disease as the patients with this rare disorder are susceptible to developing serious complications. Several patients experienced a temporary disruption in their treatment during to the pandemic due to the fear of infection. However, with the effective management of the coronavirus cases in hospitals and other healthcare settings the Fabry disease patients are slated to obtain regular treatment which will fuel the industry progression over the foreseeable future.
Market, by Treatment
The above information is provided for the following regions and countries: